drugset / Trial / NCT04703920
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
Phase 1
Completed
26 enrolled
University of Michigan Rogel Cancer Center
Acrotech Biopharma Inc. · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
This Phase 1 dose-escalation trial is to determine the safety, tolerability and recommended phase 2 dose of talazoparib in combination with belinostat in subjects with Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer.
Timeline
- Start
- 2021-03-04
- Primary completion
- 2024-12-01
- Completion
- 2025-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belinostat | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Talazoparib | Small molecule | 1 mg | Oral |